ASND Ascendis Pharma A/S
Healthcare$239.65-3.00%ClosedMarket Cap: $14.81B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
26.80
P/S
15.11
EV/EBITDA
-1935.12
DCF Value
$-4,957.90
FCF Yield
0.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.2%
Operating Margin
-0.8%
Net Margin
58.4%
ROE
-5641.9%
ROA
25.3%
ROIC
1.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $250.7M | 91.4% | $25.2M | $639.7M | $— | — |
| Q4 null | $245.2M | 88.9% | $9.8M | $-33.2M | $— | — |
| FY null | $691.7M | 85.1% | $-130.9M | $-219.0M | $— | — |
| Q3 null | $213.6M | 89.5% | $11.0M | $-61.0M | $— | — |
| Q2 null | $158.0M | 80.1% | $-53.0M | $-38.9M | $— | — |
| Q1 null | $101.0M | 82.6% | $-104.2M | $-94.6M | $— | — |
| Q4 null | $173.9M | 91.9% | $383.0K | $-38.5M | $— | — |
| FY null | $363.6M | 87.8% | $-278.8M | $-378.1M | $— | — |
| Q3 null | $57.8M | 80.6% | $-96.7M | $-99.2M | $— | — |
| Q2 null | $36.0M | 68.2% | $-133.3M | $-109.4M | $— | — |
| Q1 null | $95.9M | 92.1% | $-49.1M | $-131.0M | $— | — |
| Q4 2023 | $137.7M | 85.9% | $-36.6M | $-86.9M | $-1.53 | — |